LLYLilly(Eli) & Co

INCY heads into Q2 earnings with strong Jakafi demand, Opzelura momentum and rising royalties, fueling expectations for an earnings beat.

Eli Lilly's retatrutide meets the primary endpoint in the phase III TRIUMPH-2 & TRIUMPH-3 studies, supporting planned regulatory submissions for obesity in 2027.

Novo Nordisk is seeking a preliminary U.S. court injunction to immediately block Lilly’s advertisements for Zepbound and Mounjaro, according to a Reuters report on Friday.

RHHBY posts 6% constant-currency sales growth in the first half of 2026 as strong demand for key drugs offsets legacy declines, while FDA pipeline progress supports momentum.

LLY's blockbuster GLP-1 portfolio takes center stage as investors watch Mounjaro, Zepbound and Foundayo for clues to Q2 growth and outlook.

Retatrutide, a once-weekly triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors, met the primary endpoint in both the Triumph-2 and Triumph-3 Phase 3 studies.

Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C PR Newswire...

Drugmakers have announced 37 biotech acquisitions worth at least $1 billion this year, topping the previous annual record.

Novo Nordisk sues LLY over high-profile ads promoting Zepbound and Mounjaro, arguing newer clinical data changes the comparison as the GLP-1 rivalry intensifies.